Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
about
Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceOutcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.Hepatitis C in Argentina: epidemiology and treatment.Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antiviralsCosts of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological responseCost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature.Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysisReply
P2860
Q28072257-425C09E3-8A26-457B-8A98-6C1F5FCCF67DQ30376341-5F447B31-AC7D-4F37-A867-81DFEB9C7143Q33706886-730BD728-CAD4-444F-AD63-FFCE4C918290Q34163405-870C7ED1-9BE8-4888-A248-D09167FA91ADQ34310417-65F50DD0-125D-45E3-9132-CA17702E9CACQ37286544-B9E85FD1-7CAF-4D33-A664-55915454DAA9Q37682673-9850A72F-94DD-48AE-84F5-F4690CD2D832Q38206573-1D86F96B-5747-4B3D-A3C4-4BE3A9648225Q38470584-8C25141D-CE5E-4CCC-AE72-864A8AB02D8BQ38691333-1F292782-9B1C-483A-85CD-32CF80782DACQ42048758-3D68C424-8A2C-4B77-8EE0-0A8A461E765EQ42201264-3D2B12AC-F573-40F1-B1FF-8AFBF7076822Q45050419-965B3902-27AD-4934-8A27-8D4C0B1F7FEDQ47569740-C134A7D4-42AE-47B9-AB50-8FA5F435CE6DQ48070441-159C7E8E-5631-481C-A909-C4B31C762D44Q54254113-10A3C55A-F921-4E40-8118-2A5DE5DEB9A7Q55280669-D62821C1-FCC7-4024-B3D2-2441087AE1ECQ56371870-9A9D62F6-C2A6-4AEE-99CD-7B691DDDD934Q59149891-D7743726-4BFD-4A86-A744-8A9648CCEFEA
P2860
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Cost-effectiveness of boceprev ...... enotype 1 chronic hepatitis C.
@en
Cost-effectiveness of boceprev ...... enotype 1 chronic hepatitis C.
@nl
type
label
Cost-effectiveness of boceprev ...... enotype 1 chronic hepatitis C.
@en
Cost-effectiveness of boceprev ...... enotype 1 chronic hepatitis C.
@nl
prefLabel
Cost-effectiveness of boceprev ...... enotype 1 chronic hepatitis C.
@en
Cost-effectiveness of boceprev ...... enotype 1 chronic hepatitis C.
@nl
P2093
P1476
Cost-effectiveness of boceprev ...... enotype 1 chronic hepatitis C.
@en
P2093
Alfredo Alberti
Antonio Gasbarrini
Calogero Cammà
Giuseppe Cabibbo
Marco Enea
Matteo Ruggeri
Raffaele Bruno
Vincenza Capursi
WEF Study Group
P304
P356
10.1016/J.JHEP.2013.05.019
P577
2013-05-23T00:00:00Z